Bone Biologics Corp Warrants
BBLGW
3 hedge funds and large institutions have $557K invested in Bone Biologics Corp Warrants in 2025 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and closing their positions.
50% more funds holding
Funds holding: 2 → 3 (+1)
0.44% less ownership
Funds ownership: 1.66% → 1.22% (-0.44%)
62% less capital invested
Capital invested by funds: $1.48M → $557K (-$921K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$55.7K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$6.23K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$6.05K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Citadel Advisors
Miami,
Florida
| $557K | +$55.7K | +921 | +3% |
|
|
2
UBS Group
Zurich,
Switzerland
| $450 | +$6.23K | +103 | +258% |
|
|
3
Bank of America
Charlotte,
North Carolina
| $315 | +$6.05K | +100 | New |
|
BBLGW Hedge Fund Activity: Q1 2025 in Review
3 of the 7,461 institutional investors tracked by Wall St. Rank reported a position in Bone Biologics Corp Warrants (BBLGW) for Q1 2025, worth a combined $557K — down 62% from $1.48M a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new BBLGW positions and 0 closed out — a net gain of 1 holder — while 2 added to existing stakes and 0 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $55.7K.
- 3 institutional investors held Bone Biologics Corp Warrants (BBLGW) as of Q1 2025, up from 2 in Q4 2024.
- Funds reported $557K of Bone Biologics Corp Warrants stock for Q1 2025, down 62% quarter-over-quarter.
- 1 fund opened new Bone Biologics Corp Warrants positions in Q1 2025 and 0 closed out, a net change of +1 holder.
- The largest Bone Biologics Corp Warrants buyer in Q1 2025 was Citadel Advisors, an estimated $55.7K added.
Based on aggregated 13F filings for Q1 2025.